Experimental drug ADCT-301 tested in just 3 patients for relapsed blood cancers
NCT ID NCT04639024
First seen May 12, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This study tested a drug called ADCT-301 in 3 adults whose acute myeloid leukemia, myelodysplastic syndrome, or related blood cancer came back after a stem cell transplant. The goal was to see if the drug is safe and can help patients achieve remission. The study was stopped early, so results are very limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Health System
Durham, North Carolina, 27705, United States
Conditions
Explore the condition pages connected to this study.